European Commission approves Array's encorafenib and binimetinib combo for melanoma treatment
BOULDER -- Array BioPharma Inc . (NASDAQ: ARRY) today announced the European Commission (EC) has approved BRAFTOVI (encorafenib) in combination with MEKTOVI (binimetinib) for the treatment of... Read More
Friday September 21, 2018 0 comments
Array BioPharma names Carrie S. Cox chair of its board of directors
BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) today announced Carrie S. Cox has been named chair of its board of directors effective immediately. Cox has been appointed to the Audit and... Read More
Tuesday August 14, 2018 0 comments
Array BioPharma colorectal cancer drugs receive Breakthrough Therapy Designation from FDA
BOULDER -- Array BioPharma Inc. (NASDAQ: ARRY) today announced it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for encorafenib (BRAFTOVI),... Read More
Tuesday August 7, 2018 0 comments
Array BioPharma: European Medicines Agency recommends approval of melanoma cancer drug
BOULDER -- Array BioPharma Inc. (NASDAQ: ARRY) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending... Read More
Monday July 30, 2018 0 comments
Array BioPharma: National Comprehensive Cancer Network, FDA OKs drug combo for melanoma
BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) announced that the National Comprehensive Cancer Network (NCCN) has updated the Clinical Practice Guidelines in Oncology for Melanoma to include... Read More
Monday July 16, 2018 0 comments
Array BioPharma announces FDA approval of encorafenib and binimetinib cancer drugs
BOULDER -- Array BioPharma Inc . (Nasdaq: ARRY) announced the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI(encorafenib) capsules in combination with MEKTOVI(binimetinib)tablets... Read More
Thursday June 28, 2018 0 comments
Array BioPharma reports positive survival results for melanoma drugs
BOULDER -- Array BioPharma Inc . (Nasdaq: ARRY) andFrance-based Pierre Fabreannounced results of a study of overall survival in patients with BRAF -mutant melanoma, indicating that treatment with... Read More
Wednesday February 7, 2018 0 comments
Array’s triplet drug combination found effective for colorectal cancer treatment
BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) and Pierre Fabre today announced updated results from the 30 patient safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet... Read More
Monday January 22, 2018 0 comments
IN Sponsors
Browse
Entrepreneurial by Nature
